Supernus Pharmaceuticals reports a negative Return on Invested Capital (ROIC) of -9.12%, which is well below its Weighted Average Cost of Capital (WACC) of 6.92%. This indicates the company is not generating enough returns to cover its capital costs, leading to value destruction for shareholders. Compared to peers in the biotech sector, Supernus is the only one with a negative ROIC, highlighting its weak capital efficiency. In contrast, Ironwood Pharmaceuticals shows strong financial health with a 29.97% ROIC against a 4.46% WACC, setting a high industry benchmark.
Suja Life's stock fell sharply by 46.18% following a 391% rise in net loss and a securities law investigation, closing at $6.14 on heavy volume. Other companies like Autonomix Medical, Limbach Holdings, USANA Health Sciences, and SolarEdge Technologi...
Transocean Ltd. announced new offshore drilling contracts worth approximately $292 million in firm fixtures and an additional $1.0 billion conditional agreement with Equinor for rigs on the Norwegian shelf. These contracts extend drilling programs ac...
LivaNova's stock price target was raised to $85 following a strong Q2 performance with record revenue of $390.6 million, up 9.8%, and adjusted EPS of $1.26, beating estimates by 16.67%. The growth was driven by its Cardiopulmonary and Epilepsy segmen...
Glencore PLC reported better-than-expected Q2 results with earnings per share of $0.37 and revenue of $174.43 billion, driven by strong performance in its marketing and industrial divisions. Adjusted EBITDA surged to $10.11 billion, reflecting robust...
Cloudflare is set to report quarterly earnings with analysts expecting $0.27 EPS and $664.67 million revenue, reflecting strong growth driven by AI and edge computing innovations. Despite robust 31.55% revenue growth and 73% gross margins, the compan...
